

SHUKRA

PHARMACEUTICALS LTD.

Financial results by company

PART I (Rs. in Lukhs) Statement of Standalone Unaudited Results for the Quarter Ended 30/06/2018						
	Particulars	3 months ended		Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended
		(30/06/2018)	(31/03/2018)	(30/06/2017)	(30/06/2018)	(31/03/2018)
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Revenue from Operation	104.76	101.17	100.83	104.76	536.19
	Other income	3.46	4.54	2.01	3.46	11.15
_	Total Revenue (1 + 11)	108.22	[05.7]	102,84	108.22	547,34
IV	Expenses					
-	(a) Cost of materials consumed	12.03	15,76	25.28	12.03	124.32
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods,	(10,01)	0.00	0.00	(10,01)	0.00
	work-in-progress and stock-in-trade					
Щ	(d) Employee benefits expense	43.44	36.99	25.47	43.44	128.36
	(e) Finace Cost	0.02	3.78	0.19	0.02	4.56
	(f) Depreciation and amortisation expense	18.42	36.20	12.50	18.42	73,70
	(g) Other expenses	23.80	73.84	29.17	23.80	121.79
	Total expenses	87.70	166,57	92.61	87.70	452.73
V	Profit / (Loss)before exceptional and extraordinary items and tax (III - IV)	20.52	(60.86)	10.23	20.52	94.61
VI	Exceptional items	5.12	0.00	0.00	5.12	0.00
VII	Profit / (Loss) before extraordinary items and tax (V - VI)	15.40	(60.86)	10.23	15.40	94.61
111	Extraordinary items	0.00	0,00	0.00	0.00	0.00
IX	Profit before tax (VII- VIII)	15.40	(60.86)	10.23	15.40	94.61
			- Lauren			7.00
X	Tax expense - Provision for taxation	10.95	(45.44)	3.07	10.95	(7.72)
XI	Net Profit / (Loss) for the period (IX-X)	4,45	(15.42)	7.16	4,45	102.33
XII	Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
	Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)					
m	Total Comprehensive Income) (after tax) for the period (9+10)	4.45	(15.42)	7.16	4.45	102.33
ΚŧV	Paid up Equity Share Capital (Face value of Re. 10/- each)	156.57	156.57	156.57	156.57	156.57
χv	Other Equity excluding revaluation reserve	1413.83	1285.53	1387.20	1413,83	1366,52
(VI	Earnings per equity share:					
	(1) Basic	0.03	(0.10)	0.05	0.03	0.65
	(2) Diluted	0:03	(0.10)	0.05	0.03	0.65

CIN: L24231GJ1993PLC019079





Notes:

- 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th August, 2018
- 2. The Company has only single Reportable Business Segment.
- 3. During the quarter ended 30th June 2018, 1 complaints was received and resolved.
- 4. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
- 5. These financial statements are prepared in accordance with Indian Accounting Standards (Ind AS) under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values, the provisions of the Companies Act., 2013 ('Act') (to the extent notified) and guidelines issued by the Securities and Exchange Board of India (SEBI). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.

Date: 14/08/2018 Place: Ahmedabad By Order of the Board of Directors For Shukra Pharmaceuticals Limited

Sujay Mehta Director DIN: 02145467

CIN: L24231GJ1993PLC019079